Clinical Trial Update: Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee [Phase 3]

View source ↗

Summary

Phase 3 trial update on subcutaneous tanezumab titration dosing for moderate to severe osteoarthritis of the hip or knee, results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Hip
• Osteoarthritis of the Knee

Drugs mentioned

• Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip | Phase 3 | Status: COMPLETED | Results posted: 2019-04-23